12/21/2004 | CVHY | Moody's confirms Apogent convertible
|
8/3/2004 | HY | Apogent, Fisher Scientific complete tender offer for 61/2% notes
|
7/27/2004 | HY | Apogent says 99.8% of 61/2% notes tendered by consent deadline
|
7/13/2004 | HY | Apogent extends tender offer for 61/2% notes, ups payment
|
7/2/2004 | HY | Apogent extends tender offer for 61/2% notes
|
6/18/2004 | HY | Apogent again extends consent deadline for 61/2% notes, coincides with tender expiration
|
6/14/2004 | HY | Apogent extends consent deadline for 61/2% notes
|
5/28/2004 | HY | Apogent tenders for 61/2% notes
|
3/17/2004 | HY | Market Commentary: American Achievement, Riverdeep deals price; Fisher Scientific up on Apogent acquisition news
|
3/17/2004 | BKCVHY | Apogent to get new credit facility to refinance bank debt, bonds and convertibles
|
10/16/2003 | HY | Apogent offer expires with $318 million 8% notes tendered
|
9/25/2003 | HY | Universal Hospital Services tenders for 101/4% notes
|
9/16/2003 | HY | Apogent tenders for 8% notes
|
8/15/2003 | HY | Market Commentary: Market sleep-walks through short post-blackout session, ponders outflow; Dex deal downsized
|
8/11/2003 | BKHY | S&P raises Alcatel outlook
|
5/22/2003 | HY | New Issue: Apogent Technologies sells $250 million 10-year notes to yield 61/2%
|
5/22/2003 | HY | Market Commentary: Seven deals price; Triton PCS up on tender news; $257.7 million outflow is funds' first in weeks
|
5/20/2003 | HY | Apogent $250 million 10-year notes talked at 61/2%-63/4%, pricing Thursday
|
5/20/2003 | HY | Market Commentary: El Paso, Rhodia price mega-deals; Hard Rock, others also appear; new-deals dominate secondary
|
5/13/2003 | BKHY | S&P rates Vertis notes B-
|
5/13/2003 | HY | Apogent to launch $250 million 10-year deal on Wednesday
|
5/13/2003 | HY | Market Commentary: Muzak, Rite Aid price deals; secondary still muted
|
5/9/2003 | HY | S&P puts Prestolite on positive watch
|
4/25/2003 | HY | Apogent Technologies to bring $250 million 10-year notes in first half of May
|
4/25/2003 | HY | Market Commentary: Firm tone continues; asbestos names up as deal seen near; Cinemark brings $210 million add-on
|